Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression
K Fousek, LA Horn, C Palena - Pharmacology & therapeutics, 2021 - Elsevier
Tumor progression relies on the ability of cancer cells to effectively invade surrounding
tissues and propagate. Among the many mechanisms that contribute to tumor progression is …
tissues and propagate. Among the many mechanisms that contribute to tumor progression is …
[HTML][HTML] Advances and challenges in the treatment of esophageal cancer
S He, J Xu, X Liu, Y Zhen - Acta Pharmaceutica Sinica B, 2021 - Elsevier
Esophageal cancer (EC) is one of the most common cancers with high morbidity and
mortality rates. EC includes two histological subtypes, namely esophageal squamous cell …
mortality rates. EC includes two histological subtypes, namely esophageal squamous cell …
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
X Wang, F Wang, M Zhong, Y Yarden, L Fu - Molecular cancer, 2020 - Springer
Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies (Abs) and anti-cytotoxic
T lymphocyte antigen 4 (CTLA-4) Abs, are effective for patients with various cancers …
T lymphocyte antigen 4 (CTLA-4) Abs, are effective for patients with various cancers …
[HTML][HTML] The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a
new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic …
new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic …
Immune checkpoint inhibitors promising role in cancer therapy: Clinical evidence and immune-related adverse events
The advent of immune checkpoint inhibitors (ICIs) has led to noteworthy progressions in the
management of diverse cancer types, as evidenced by the pioneering “ipilimumab” …
management of diverse cancer types, as evidenced by the pioneering “ipilimumab” …
Fecal microbiota transplantation effectively cures a patient with severe bleeding immune checkpoint inhibitor-associated colitis and a short review
M Chen, M Liu, C Li, S Peng, Y Li, X Xu, M Sun… - Frontiers in …, 2022 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have opened up a new way for tumor therapy but
simultaneously led to the occurrence of immune-related adverse events. We report a case of …
simultaneously led to the occurrence of immune-related adverse events. We report a case of …
Cutaneous adverse reactions to anti–PD-1 treatment—A systematic review
AB Simonsen, J Kaae, E Ellebaek, IM Svane… - Journal of the American …, 2020 - Elsevier
The use of the humanized monoclonal anti–programmed cell death 1 antibodies
pembrolizumab and nivolumab as potent anticancer therapies is rapidly increasing …
pembrolizumab and nivolumab as potent anticancer therapies is rapidly increasing …
Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA
A Millet, N Khoudour, P Bros, D Lebert, G Picard… - Talanta, 2021 - Elsevier
Nivolumab is a fully human immunoglobulin G4 used for the treatment of several advanced
solid cancers as immune checkpoint inhibitors. There are some challenges for the …
solid cancers as immune checkpoint inhibitors. There are some challenges for the …
New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review
C Bachmann - Cancers, 2023 - mdpi.com
Simple Summary In ovarian cancer, about 70% of patients experience relapse despite
primary cytoreductive surgery and platinum-based chemotherapy. The occurrence of …
primary cytoreductive surgery and platinum-based chemotherapy. The occurrence of …
RNA based approaches to profile oncogenic pathways from low quantity samples to drive precision oncology strategies
Precision treatment of cancer requires knowledge on active tumor driving signal
transduction pathways to select the optimal effective targeted treatment. Currently only a …
transduction pathways to select the optimal effective targeted treatment. Currently only a …